Technology Bundle ID
TAB-3014

Albumin Binding Immunomodulatory Compositions

Linked ID
E-149-2016-0
Lead Inventors
Xiaoyuan Chen (NIBIB)
Co-Inventors
Guizhi Zhu (NIBIB)
Development Stages
Discovery
Development Status
Early-stage
ICs
NIBIB
The invention relates to molecules wherein Evan’s Blue dye is chemically conjugated to CpG Oligonucleotides that elicit anti-tumoral or infection fighting immunity. Evans Blue, a symmetric azo dye, has high binding affinity to albumin. Albumin binding ability of Evans blue is utilized with CpGs and tumor-specific antigens, in order to leverage endogenous albumin that increases the safety and the potency of molecular vaccines. As such, the molecular entities provided here enable efficient delivery and prolonged retention in lymph nodes and reduce systemic toxicity of Evans Blue and enhanced the therapeutic potency of molecular vaccines.
Commercial Applications
  • Cancer therapeutics
  • Infectious disease therapeutics
  • Lymph node specificity
  • Higher stability/Lower toxicity

Request More Info

Licensing Contact: